1,1-Diethylguanidine → 5-(2-(Diethylamino)pyrimidin-4-yl)-4-methylthiazol-2-amine
反応式
[OH-].[Na+].CN(C)[CH:5]=[CH:6][C:7]([C:9]1[S:13][C:12]([N:14]=CN(C)C)=[N:11][C:10]=1[CH3:19])=O.[CH2:21]([N:23]([CH2:27][CH3:28])[C:24]([NH2:26])=[NH:25])[CH3:22]>COCCO>[NH2:14][C:12]1[S:13][C:9]([C:7]2[CH:6]=[CH:5][N:26]=[C:24]([N:23]([CH2:27][CH3:28])[CH2:21][CH3:22])[N:25]=2)=[C:10]([CH3:19])[N:11]=1参加物
5
反応条件
- 温度
- 125 °C
実験手順
Powdered sodium hydroxide (150 mg) is added to a solution of N′-[5-(3-dimethylamino-acryloyl)-4-methyl-thiazol-2-yl]-N,N-dimethyl-formamidine (0.5 g, prepared as described by S. Wang et al J. Med. Chem. 2004, 47, 1662-1675.) and 1,1-diethylguanidine (259 mg) in 2-methoxyethanol (1.9 ml) and the mixture heated at 125° C. for 1 hour with stirring. The reaction mixture is concentrated under vacuum and purified by normal phase chromatography, eluent; DCM/EtOAc, to give the title compound. ESI-MS: M+H 264 and M−H 262.
後処理
- concentrationThe reaction mixture is concentrated under vacuum
- custompurified by normal phase chromatography, eluent
出典と根拠
- ORDレコード
- ord-ed43e83697a14da49638f6b93a40e2c6
- 出典データセット
- uspto-grants-2015_01
- 特許番号
- US08940771B2
反応ノート
読み込み中…